Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer

Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to standard treatments, such as docetaxel and enzalutamide. Histone deacetylase (HDAC) inhibitors showed promising results in hematological malignancies, but they failed in solid tumors s...

Descripción completa

Detalles Bibliográficos
Autores principales: Rana, Zohaib, Diermeier, Sarah, Hanif, Muhammad, Rosengren, Rhonda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168248/
https://www.ncbi.nlm.nih.gov/pubmed/32019149
http://dx.doi.org/10.3390/biomedicines8020022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168248/
https://www.ncbi.nlm.nih.gov/pubmed/32019149
http://dx.doi.org/10.3390/biomedicines8020022

Ejemplares similares